Challenge
As our clients’ blockbuster approached loss of exclusivity, they had made significant investment to maintain leadership through acquisition and development of a suite of new assets, all at the early phases of development.
In a highly competitive market, it was critical to have the right assets in their pipeline and prioritised development of those with the best opportunity to retain their leadership both commercially and in terms of impact to health outcomes.
Solution
Lucid developed a robust, cross-functional approach to set the strategic direction for their emerging pipeline
This approach included:
- Full design of the moderated process incl. data and analysis needs and stakeholder involvement and engagement
- Market assessment, immersion & landscape analyses for each asset including MoA, clinical inertia and unmet needs, competitor profiling, guideline and professional body analysis
- Integrated positioning by asset and for portfolio
- Scientific communications platform by asset and portfolio
- Mapping core communication, story flow & tactical planning
- Onboarding, immersion and management of client operational, cross-functional alignment
Outcome
A clear portfolio strategy informing indication and asset prioritisation, optimised asset positioning within highly competitive market, aligned evidence generation strategies and internal team alignment to portfolio strategy.